Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Debt to Equity Ratio
- The debt to equity ratio exhibited moderate fluctuations over the analyzed quarters. Beginning at 0.42 in early 2018, it showed slight increases and decreases throughout 2018 and early 2019, maintaining a level between 0.43 and 0.48. A significant upward shift occurred starting in the first quarter of 2020, with the ratio peaking around 0.69 in late 2020 and early 2021. Subsequently, there was a gradual reduction, with the ratio declining to 0.49 by the third quarter of 2022. The trend including operating lease liabilities follows a similar pattern but tends to be marginally higher, reflecting the impact of lease obligations on financial leverage.
- Debt to Capital Ratio
- This ratio remained relatively stable around the 0.30 level from 2018 through early 2020. A noticeable increase commenced in the first quarter of 2020, peaking around 0.41 in late 2020 and early 2021, which aligns with the rise observed in the debt to equity ratio. After this peak, the debt to capital ratio steadily decreased, reaching 0.33 by the third quarter of 2022. Inclusion of operating lease liabilities results in slightly higher ratios consistently, but the overall trend mirrors that of the standard debt to capital ratio.
- Debt to Assets Ratio
- The debt to assets ratio was stable, near 0.23, through 2018 and early 2019, then began a moderate increase in early 2020, rising to around 0.30-0.31 through 2021. Following this increase, the ratio marginally decreased to 0.25 by the third quarter of 2022. Accounting for operating lease liabilities slightly elevates the ratios but does not substantially alter the observed trend.
- Financial Leverage Ratio
- The financial leverage ratio shows a consistent upward trend from 1.86 in the first quarter of 2018 to a peak around 2.32 in late 2020. This upward trend signifies an increasing use of debt financing relative to equity. After the peak, there is a gradual decline, with the ratio falling to approximately 1.95 by the third quarter of 2022, indicating a reduction in leverage over the most recent quarters.
- Overall Analysis
- Overall, the financial leverage and debt-related ratios indicate a phase of increasing leverage beginning in early 2020, peaking near the end of 2020 and early 2021, likely reflecting strategic financing decisions or responses to external conditions during that period. From 2021 onward, the company appears to be gradually reducing its leverage and improving capital structure stability. The inclusion of operating lease liabilities consistently results in slightly higher leverage metrics, underscoring the importance of lease obligations in the financial risk profile. Despite these fluctuations, the leverage ratios remain moderate and show careful management of financial risk in the latest periods.
Debt Ratios
Debt to Equity
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of notes payable | |||||||||||||||||||||||||
| Notes payable, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total Biogen Inc. shareholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Debt to equity = Total debt ÷ Total Biogen Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals notable developments in the company's capital structure and leverage trends over the observed periods. The total debt demonstrates relative stability from 2018 through early 2020, fluctuating slightly around the 5.9 to 6.0 billion US dollars mark. However, a pronounced increase occurs in mid-2020, where total debt rises significantly to approximately 7.4 billion US dollars and remains at this elevated level through the end of 2021. Starting in early 2022, a marked reduction in total debt is observable, declining to approximately 6.3 billion US dollars by the third quarter of 2022.
Shareholders’ equity exhibits more variability, with fluctuations observed throughout the timeframe. Initially, equity stands near 14 billion US dollars at the end of the first quarter of 2018 but decreases in the middle of the year before partially recovering by the end of 2018. The year 2019 shows some instability, with equity oscillating but generally trending lower than earlier levels. From the beginning of 2020, equity follows a downward trajectory, hitting its lowest point in the fourth quarter of 2020 at around 10.7 billion US dollars. Following this trough, the equity base stabilizes and experiences gradual recovery through 2021 and into 2022, reaching approximately 12.8 billion US dollars by the third quarter of 2022.
The debt-to-equity ratio reflects these movements closely. Initially trending between 0.42 and 0.48, the ratio increases sharply in mid-2020, peaking near 0.7 and maintaining elevated levels through 2021. This higher leverage indicates increased reliance on debt financing relative to equity during this period. In 2022, the ratio declines steadily, falling back below 0.5 by the third quarter, aligning with both the reduction in debt and the strengthening equity position.
Overall, the data portrays a period of increased leverage beginning in mid-2020, characterized by a surge in debt coupled with a declining equity base, which likely signals strategic financial decisions or responses to external factors necessitating additional borrowing. The subsequent reversal of this pattern in 2022 indicates efforts to deleverage and reinforce the equity base, suggesting improved financial stability and potentially reduced financial risk moving forward.
Debt to Equity (including Operating Lease Liability)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of notes payable | |||||||||||||||||||||||||
| Notes payable, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Long-term operating lease liabilities | |||||||||||||||||||||||||
| Total debt (including operating lease liability) | |||||||||||||||||||||||||
| Total Biogen Inc. shareholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Biogen Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total debt (including operating lease liability)
- The total debt level remained relatively stable from March 2018 through March 2020, fluctuating slightly around 5.9 to 6.4 billion US dollars. Beginning June 2020, total debt increased significantly, peaking near 7.8 billion US dollars in December 2020. After this peak, a gradual decline in debt is observed, with the balance reducing to approximately 6.6 billion US dollars by September 2022. This indicates a period of increased leverage followed by efforts to deleverage in recent quarters.
- Total Biogen Inc. shareholders’ equity
- Shareholders’ equity showed variability over the period. Starting near 14 billion US dollars in March 2018, there was a notable decline in equity through June 2020, falling to around 10.7 billion US dollars. From mid-2020 onward, the equity gradually recovered and increased steadily, reaching approximately 12.8 billion US dollars by September 2022. This pattern suggests initial equity losses or distributions followed by stabilization and growth.
- Debt to equity ratio (including operating lease liability)
- The debt to equity ratio exhibited an upward trend from 0.42 in March 2018, rising gradually to about 0.51 by March 2020. A sharp increase occurred in the next two quarters, peaking around 0.73 in late 2020 and persisting near that level through 2021. However, a declining trend is evident starting in early 2022, with the ratio dropping to 0.52 by September 2022. This indicates that leverage increased significantly during 2020 before the company began reducing its relative debt exposure compared to equity more recently.
- Summary insights
- The data reflects a period of relatively stable debt followed by a substantial increase around 2020, likely linked to strategic or operational needs during that period. Equity experienced a corresponding decline during the same timeframe but showed signs of recovery thereafter. The debt to equity ratio confirms increased leverage during 2020 and 2021, with a subsequent de-leveraging trend starting in 2022. Overall, these patterns suggest that the company took on additional debt around 2020 but has since worked to strengthen its equity position and manage its leverage towards a more balanced financial structure.
Debt to Capital
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of notes payable | |||||||||||||||||||||||||
| Notes payable, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total Biogen Inc. shareholders’ equity | |||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several noteworthy trends regarding the company's debt and capital structure from March 2018 through September 2022.
- Total Debt
- Total debt remained relatively stable from March 2018 to March 2020, fluctuating narrowly around the 5.9 million US$ in thousands mark. However, a significant increase occurred in June 2020, where total debt rose sharply to approximately 7.42 million US$ in thousands and stayed near this elevated level through December 2021. From March 2022 onwards, total debt began to decline, reaching approximately 6.28 million US$ in thousands by September 2022.
- Total Capital
- Total capital exhibited more variability throughout the period. Starting at around 19.99 million US$ in thousands in March 2018, it dropped notably by June 2018 to about 18.19 million and oscillated near this range with some recoveries and declines over subsequent quarters. Noteworthy is a steady decline starting in December 2020 through to September 2021, reaching a low of about 17.7 million US$ in thousands, followed by a gradual recovery between December 2021 and June 2022. Total capital slightly declined again by September 2022 to roughly 19.05 million US$ in thousands.
- Debt to Capital Ratio
- The debt to capital ratio displayed a generally stable pattern near 0.30 to 0.33 from March 2018 to March 2020. This was followed by a marked increase coinciding with the jump in total debt in mid-2020, peaking around 0.41 in September to December 2020 and remaining elevated (0.39 to 0.41) through September 2021. A downward trend is visible thereafter, as the ratio decreased steadily to about 0.33 by September 2022, reflecting the reduction in debt and recovery in capital.
In summary, the company underwent a period of increased leverage beginning in mid-2020, characterized by a substantial rise in total debt and a corresponding increase in the debt to capital ratio. Post this period, the firm focused on deleveraging, supported by a reduction in total debt and partial recovery in total capital, leading to a gradual normalization of the leverage ratio by late 2022.
Debt to Capital (including Operating Lease Liability)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of notes payable | |||||||||||||||||||||||||
| Notes payable, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Long-term operating lease liabilities | |||||||||||||||||||||||||
| Total debt (including operating lease liability) | |||||||||||||||||||||||||
| Total Biogen Inc. shareholders’ equity | |||||||||||||||||||||||||
| Total capital (including operating lease liability) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
- Total Debt (Including Operating Lease Liability)
- The total debt exhibited relative stability from March 2018 through March 2020, maintaining values slightly above 5.9 billion US dollars initially and increasing modestly to approximately 6.36 billion US dollars by the end of 2019. A sharp increase is notable starting in June 2020, with debt rising substantially to roughly 7.8 billion US dollars and remaining near that elevated level through December 2020. Subsequently, a gradual but consistent decline in total debt is observable from March 2021 onward, decreasing steadily to around 6.63 billion US dollars by September 2022.
- Total Capital (Including Operating Lease Liability)
- Total capital demonstrated a more fluctuating pattern over the period under review. Initial capital amounts in early 2018 ranged around 18.1 to 20.0 billion US dollars, with moderate volatility thereafter. The figures show a general downward trend from early 2019 to the end of 2020, with dips below 19.0 billion US dollars occurring in most quarters towards the end of 2020. In 2021, the total capital remained relatively stable, hovering near 18.0 to 18.5 billion US dollars. A gradual recovery ensued in 2022, with capital increasing to approximately 19.4 billion US dollars by the third quarter.
- Debt to Capital Ratio (Including Operating Lease Liability)
- The debt to capital ratio remained relatively stable in the range of 0.30 to 0.33 during 2018 and the early part of 2019, indicating a moderate level of leverage relative to capital. A noticeable uptick begins around the first quarter of 2020, accelerating sharply to peak ratios of approximately 0.42 during 2020 and throughout 2021. This elevated leverage highlights a period where debt comprised a larger portion of total capital. In 2022, a decline in the ratio is observed, falling from about 0.42 down to approximately 0.34 by the third quarter, indicating a deleveraging trend with debt reducing faster relative to capital.
- Overall Financial Leverage and Capital Structure Trends
- The data indicates an interim phase of increased borrowing in 2020, likely reflecting strategic or operational responses to external factors, as evidenced by the sharp rise in total debt and consequently higher leverage ratios. The subsequent reduction of debt levels and decreasing debt to capital ratio through 2021 and into 2022 suggests a focus on deleveraging and strengthening of the capital base. Meanwhile, total capital experienced some variability but shows signs of recovery in the latest periods. These trends collectively point to a period of elevated financial leverage followed by cautious financial management aiming to restore capital structure balance.
Debt to Assets
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of notes payable | |||||||||||||||||||||||||
| Notes payable, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt remained relatively stable from March 2018 through March 2020, fluctuating slightly around 5.9 to 6.0 billion US dollars. However, there was a notable increase in debt beginning in the second quarter of 2020, rising sharply to approximately 7.4 billion US dollars and maintaining that elevated level through the end of 2021. Starting in early 2022, the total debt decreased significantly, dropping to 6.3 billion US dollars by the third quarter of 2022.
- Total Assets
- Total assets displayed fluctuations over the observed periods, starting at around 26.1 billion US dollars in the first quarter of 2018. There was a decline in mid-2018, followed by a recovery towards the end of 2019, peaking near 27.5 billion US dollars. From early 2020 onwards, a downward trend in assets became evident, with values declining gradually to a low near 23.8 billion US dollars by the end of 2021. In 2022, total assets showed signs of recovery, increasing to approximately 25.1 billion in the second quarter before slightly decreasing to 24.9 billion by the third quarter.
- Debt to Assets Ratio
- The debt to assets ratio was generally stable around 0.22 to 0.25 from early 2018 through early 2020, reflecting a balanced level of leverage relative to asset size. Starting in mid-2020, the ratio increased sharply, reaching approximately 0.30 to 0.31 during late 2020 and most of 2021, indicating higher leverage during this period. In 2022, the ratio showed a downward trend, declining to about 0.25 by the third quarter, which aligns with the reduction in total debt and modest asset recovery observed in the same timeframe.
- Overall Analysis
- There is a clear pattern of increased leverage beginning in mid-2020, likely associated with external or strategic financial decisions, as evidenced by a marked rise in total debt and a concomitant increase in the debt to assets ratio. This elevated leverage persisted relatively consistently through 2021. Meanwhile, total assets declined during this period, which further contributed to the increased leverage ratio. The trends in 2022 demonstrate a shift toward deleveraging, with significant debt reduction and asset stabilization or recovery, resulting in an improved debt to assets ratio. This suggests a strategic movement to strengthen the balance sheet by reducing reliance on debt financing while stabilizing the asset base.
Debt to Assets (including Operating Lease Liability)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of notes payable | |||||||||||||||||||||||||
| Notes payable, excluding current portion | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Long-term operating lease liabilities | |||||||||||||||||||||||||
| Total debt (including operating lease liability) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several distinct trends in the company’s leverage and asset base over the reported periods.
- Total Debt (including operating lease liability)
- The total debt figures remained relatively stable from the first quarter of 2018 through the first quarter of 2020, fluctuating narrowly around the range of approximately $5.9 billion to $6.4 billion. However, from the second quarter of 2020, there was a noticeable increase, peaking near $7.8 billion by the end of 2020 and early 2021. Subsequently, the debt showed a gradual declining trend through 2022, decreasing to around $6.6 billion by the third quarter of 2022.
- Total Assets
- Total assets exhibited more variability across the timeframe. Initially, they started near $26.1 billion and showed a downward trend in 2018 before recovering and reaching a high near $27.5 billion in late 2019. After this peak, assets began to decline steadily through 2020 and into mid-2021, reaching lows in the $23.8 to $24.5 billion range. Notably, there was a recovery in mid-2022, with total assets increasing again toward $25 billion by the third quarter of 2022.
- Debt to Assets Ratio (Including Operating Lease Liability)
- The leverage ratio was relatively low and stable at about 0.23 to 0.25 from early 2018 through early 2020. A significant increase occurred starting in the second quarter of 2020, with the ratio rising sharply to exceed 0.30, peaking at approximately 0.32 through 2021 and early 2022. This indicates an increased leverage position relative to the asset base during this period. In the latter part of 2022, the ratio declined to around 0.27, reflecting the aforementioned decrease in debt relative to asset values.
Overall, the company increased its debt load significantly around early 2020, likely due to external factors impacting liquidity or financing strategies. Despite fluctuations in the asset base, the increased debt proportion led to higher leverage throughout 2020 and 2021. More recently, both total debt and the leverage ratio have declined, suggesting a partial deleveraging or repayment effort, combined with a modest recovery in assets. This changing financial structure may impact future financial risk and flexibility.
Financial Leverage
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Total Biogen Inc. shareholders’ equity | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Financial leverage = Total assets ÷ Total Biogen Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total assets
- Total assets showed fluctuations over the observed periods, initially decreasing from approximately 26.1 billion US dollars at the end of March 2018 to a low of about 23.8 billion US dollars by March 2021. Following this, there was some recovery with assets rising again to around 25.1 billion by June 2022, before slightly declining to roughly 24.9 billion by September 2022. This pattern indicates a period of contraction followed by partial stabilization in the asset base.
- Total shareholders’ equity
- Shareholders’ equity mirrored a somewhat similar trend, with a substantial decline from approximately 14.1 billion US dollars in March 2018 to a trough near 10.4 billion US dollars in September 2021. However, from that low point onwards, equity values began to recover, reaching an estimated 12.8 billion US dollars by September 2022. This suggests the company was able to rebuild its equity base after a prolonged period of decline.
- Financial leverage
- The financial leverage ratio steadily increased from about 1.86 at the end of March 2018 to a peak of approximately 2.32 in September 2020, signaling higher reliance on debt relative to equity during that period. Subsequently, leverage began to decline moderately, reaching near 1.95 by September 2022. This decrease may indicate improving capitalization or a strategy to reduce financial risk by lowering debt levels relative to equity.
- Overall analysis
- The data reflects a challenging phase with diminishing assets and equity, coupled with increasing financial leverage, peaking around 2020. The subsequent recovery in equity and reduction in leverage suggest a strategic response to enhance financial stability. The company appears to have managed its capital structure more conservatively in the later periods, reducing leverage and partially restoring equity and asset values.